Biotech Ardelyx Beats Shareholder Suit Over Kidney Drug
By Katryna Perera · March 18, 2024, 7:23 PM EDT
Biotechnology company Ardelyx Inc. has for now beaten a shareholder class action alleging the company and its top brass made false and misleading statements about regulatory approval of Ardelyx's drug for...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login